Hangzhou Rongli Pharmaceutical Technology Co., Ltd.

Using ACR20 as the primary efficacy indicator, a randomized, double-blind, placebo-controlled, multicenter, dose-finding trial design was adopted to preliminarily evaluate the efficacy and safety of different doses of Smilax glabra total glycosides tablets in the treatment of rheumatoid arthritis (dampness obstruction syndrome) and to explore the optimal effective and safe dose.

To evaluate the safety profile and efficacy of AL3810 in patients with locally advanced or metastatic gastric cancer, hepatocellular carcinoma, or nasopharyngeal carcinoma. To determine the pharmacokinetic (PK) profile of AL3810 and its potential metabolites after oral administration in patients with locally advanced or metastatic gastric cancer, hepatocellular carcinoma, or nasopharyngeal carcinoma. To determine the pharmacodynamic (PD) profile of AL3810. Optional: Pharmacogenomic (PG) analysis of interpatient differences in protein-coding genes involved in absorption/distribution/metabolism/excretion (ADME)

The pharmacokinetic parameters and relative bioavailability of lacosamide tablets (specification: 100 mg) developed by Jiangxi Qingfeng Pharmaceutical Co., Ltd. and lacosamide tablets (trade name: VIMPAT; specifications: 100 mg, 200 mg) produced by the original research company UCB were investigated, and whether the two were bioequivalent when administered on an empty stomach or after a meal in healthy subjects was evaluated.